<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04244383</url>
  </required_header>
  <id_info>
    <org_study_id>ŸêAssiutU</org_study_id>
    <nct_id>NCT04244383</nct_id>
  </id_info>
  <brief_title>Expression of Inflammasomes in HCV Patients</brief_title>
  <acronym>Inflammasome</acronym>
  <official_title>Expression of Inflammasomes in HCV Patients Before and After Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis C virus has been identified a quarter of a decade ago as a leading cause of chronic
      viral hepatitis that can lead to cirrhosis and hepatocellular carcinoma. Only a minority of
      patients can clear the virus spontaneously during acute infection. Elimination of HCV during
      acute infection correlates with a rapid induction of innate and a delayed induction of
      adaptive immune responses. The majority of patients is unable to clear the virus and develops
      viral persistence despite the ongoing innate and adaptive immune response. The virus usually
      develops several strategies to escape these immune responses.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>chronic hepatitis C virus patients</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in the exprssion level of inflammasomes</measure>
    <time_frame>6 monthes</time_frame>
    <description>observe the changes in the exprssion level of inflammasomes in the selected chronic HCV patients before treatment with Sofosbuvir 400 mg and Daclatasvir 60 mg daily for 12 weeks and after sustained virological response at 12 weeks following the end of treatment (SVR12).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>chronic hepatitis C virus patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 chronic hepatitis C virus patients taking will be trated with direct acting antiviral treatment with three months regimen (Sofosbuvir + Daclatasvir).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treated chronic hepatitis C virus patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the selected 50 chronic hepatitis C virus patients received direct acting antivirals: Sofosbuvir 400 mg and Daclatasvir 60 mg daily for 12 weeks and were assessed for sustained virological response at 12 weeks following the end of treatment (SVR12).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>interleukin IL-1beta and interleukin IL-18</intervention_name>
    <description>pro-inflammatory cytokines measured in the serum</description>
    <arm_group_label>chronic hepatitis C virus patients</arm_group_label>
    <arm_group_label>treated chronic hepatitis C virus patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hepatitis C virus patients.

          -  Patients do not start treatment protocol.

        Exclusion Criteria:

          -  Pregnant women.

          -  Hepato-cellular carcinoma patients.

          -  Autoimmune disease patients.

          -  Patients with liver cirrhosis.

          -  Patients who refuse to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asmaa Salah El-dien Gaber, lecturer</last_name>
    <role>Principal Investigator</role>
    <affiliation>participator in the research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed Ahmed Medhat, lecturer</last_name>
    <role>Principal Investigator</role>
    <affiliation>participator in the research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sara Fergany Abd El-hamid, student</last_name>
    <role>Principal Investigator</role>
    <affiliation>participator in the research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Khaled Mohammed Hassanein, professor</last_name>
    <phone>01118508060</phone>
    <email>khaledhassanein70@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helal Foad Hetta, lecturer</last_name>
    <phone>0100311412</phone>
    <email>helalhetta@yahoo.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Chen H, He G, Chen Y, Zhang X, Wu S. Differential Activation of NLRP3, AIM2, and IFI16 Inflammasomes in Humans with Acute and Chronic Hepatitis B. Viral Immunol. 2018 Nov;31(9):639-645. doi: 10.1089/vim.2018.0058. Epub 2018 Sep 15.</citation>
    <PMID>30222506</PMID>
  </reference>
  <reference>
    <citation>Kanneganti TD. Central roles of NLRs and inflammasomes in viral infection. Nat Rev Immunol. 2010 Oct;10(10):688-98. doi: 10.1038/nri2851. Epub 2010 Sep 17. Review.</citation>
    <PMID>20847744</PMID>
  </reference>
  <reference>
    <citation>YingLi H, Shumei L, Qian Y, Tianyan C, Yingren Z, Wei C. Proapoptotic IL-18 in patients with chronic hepatitis C treated with pegylated interferon-alpha. Clin Exp Med. 2009 Jun;9(2):173-8. doi: 10.1007/s10238-009-0041-5. Epub 2009 Feb 24.</citation>
    <PMID>19238512</PMID>
  </reference>
  <reference>
    <citation>Burchill MA, Roby JA, Crochet N, Wind-Rotolo M, Stone AE, Edwards MG, Dran RJ, Kriss MS, Gale M Jr, Rosen HR. Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy. PLoS One. 2017 Oct 17;12(10):e0186213. doi: 10.1371/journal.pone.0186213. eCollection 2017.</citation>
    <PMID>29040318</PMID>
  </reference>
  <reference>
    <citation>Shi J, Li Y, Chang W, Zhang X, Wang FS. Current progress in host innate and adaptive immunity against hepatitis C virus infection. Hepatol Int. 2017 Jul;11(4):374-383. doi: 10.1007/s12072-017-9805-2. Epub 2017 Jun 22. Review.</citation>
    <PMID>28643186</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Aya Fergany</investigator_full_name>
    <investigator_title>princible inverstigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

